Journal of Diagnostics Concepts & Practice >

2022 , Vol. 21 >Issue 04: 450 - 455

DOI: https://doi.org/10.16150/j.1671-2870.2022.04.006

Original articles

Characteristcs of mycobacterial species distribution in acquired immunodeficiency syndrome patients with mycobacterial infection in Shanghai

Expand
  • 1. School of Public Health, Bengbu Medical College, Anhui Bengbu 233000, China
    2. Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China
    3. The Second Affiliated Hospital of Southern University of Science and Technology (The Third People’s Hospital of Shenzhen), Guangdong Shenzhen 518000, China

Received date: 2022-04-01

  Online published: 2022-11-07

Fold

Abstract

Objective: To analyze the distribution of mycobacterium(MB) species in patients with AIDS and with MB. Methods: From January 1, 2012 to December 31, 2021, a total of 9 619 outpatients and inpatients with AIDS and with mycobacterial culture in the Shanghai Public Health Clinical Center were enrolled. The clinical data of those with positive culture of MB were analyzed, and the isolated strains were obtained. The strains were identified using the immunocolloidal gold method of MPB64, a specific secreted protein of tubercle bacilli, or mycobacterial sequencing (16S rDNA) method, and the distribution characteristics of strains in AIDS patients with MB infection were analyzed. Results: A total of 1 478 patients got a positive result of MB culture and among them, 1 367 patients obtained an identified strain species result, including 494 (36.1%) cases of mycobacterium tuberculosis complex (MTBC), 838 (61.3%) cases of non-tuberculous mycobacteria (NTM), and 35 (2.6%) cases of MTBC combined with NTM. The year-by-year composition of NTM (patients with mixed MTBC and NTM infection are not included) from 2012 to 2021 were 55.2%(53/96), 65.5% (78/119), 66.2% (90/136), 55.1% (70/127), 61.6% (93/151), 66.1% (111/168), 58.9% (99/168), 61.8% (94/152), 63.6%(77/121), and 56.6% (73/129). Sputum was the main tissue specimen, accounted for 68.0% (336/494), 78.0% (654/838) and 88.6% (31/35) in patients with MTBC, NTM, mixed MTBC-NTM infection, respectively. One thousand two hundred and seventy-one patients with positive MB culture were admitted to the Department of Infection and Immunology, of which the NTM accounted for 58.5%(743/1 271). Conclusions: From 2012 to 2021, the positive rate of MB culture among AIDS patients in Shanghai is 15.4%(1 478/9 619), of which the composition ratio of NTM are higher than that of MTBC over the years. This suggests that clinicians should pay high attention to the diagnosis and treatment of NTM.

Key words： Human immunodeficiency virus/Acquired immune deficiency syndrome; Mycobacterium tuberculosis; Non-tuberculous mycobacteria

Cite this article

HU Jingjing, LÜ Haiwei, XUN Jingna, SHEN Yinzhong, LIU Li, LU Hongzhou . Characteristcs of mycobacterial species distribution in acquired immunodeficiency syndrome patients with mycobacterial infection in Shanghai[J]. Journal of Diagnostics Concepts & Practice, 2022 , 21(04) : 450 -455 . DOI: 10.16150/j.1671-2870.2022.04.006

References

[1] Haworth CS, Banks J, Capstick T, et al. British thoracic society guideline for the management of non-tuberculous mycobacterial pulmonary disease(NTM-PD)[J]. BMJ Open Respir Res, 2017, 4(1):e000242.
[2] Bryant JM, Grogono DM, Rodriguez-Rincon D, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium[J]. Scie-nce, 2016, 354(6313):751-757.
[3] Agizew T, Basotli J, Alexander H, et al. Higher-than-expected prevalence of non-tuberculous mycobacteria in HIV setting in Botswana: Implications for diagnostic algorithms using Xpert MTB/RIF assay[J]. PLoS One, 2017, 12(12):e0189981.
[4] Rivero-Lezcano OM, González-Cortés C, Mirsaeidi M. The unexplained increase of nontuberculous mycobacteriosis[J]. Int J Mycobacteriol, 2019, 8(1):1-6.
[5] Koenig SP, Kim A, Shepherd BE, et al. Increased mortality after tuberculosis treatment completion in persons living with human immunodeficiency virus in Latin America[J]. Clin Infect Dis, 2020, 71(1):215-217.
[6] Kobayashi T, Nishijima T, Teruya K, et al. High mortality of disseminated non-tuberculous mycobacterial infection in HIV-infected patients in the antiretroviral therapy era[J]. PLoS One, 2016, 11(3):e0151682.
[7] LIN Q, MO L, SU X, et al. Distribution characteristics of drug susceptibility test results of tuberculosis and non-tuberculous bacilli in patients with opportunistic infections of AIDS[J]. J Tuberc Res, 2021, 9(4):256-265.
[8] 王娟娟, 施旭东, 肖园园, 等. 南京地区HIV/AIDS患者分枝杆菌感染分布及耐药性分析[J]. 临床检验杂志, 2021, 39(2):148-150.
[8] Wang JJ, Shi XD, Xiao YY, et al. Analysis of mycobacterium infection distribution and drug resistance in HIV/AIDS patients in Nanjing[J]. Chin J Clin Lab Sci, 2021, 39(2):148-150.
[9] 邓西子, 唐小平, 雷杰, 等. 广州地区艾滋病患者合并感染分枝杆菌菌种的分布特征[J]. 中华传染病杂志, 2015(6):331-334.
[9] Deng XZ, Tang XP, Lei J, et al. The mycobacterial species distribution in acquired immunodeficiency syndrome patients in Guangzhou[J]. Chin J Infect Dis, 2015(6):331-334.
[10] 邓晓军, 张峣, 杨炼, 等. 艾滋病合并非结核分枝杆菌感染的流行病学调查与临床特征分析[J]. 中外医疗, 2013, 32(24):53-54,56.
[10] Deng XJ, Zhang X, Yang L, et al. Epidemiological investigation and clinical characteristics of AIDS co-infection with non-tuberculous mycobacteria[J]. China Foreign Med Treat, 2013, 32(24):53-54.
[11] 黄文滨, 张满娥, 卢志华, 等. 福建省龙岩市333份分枝杆菌菌种鉴定结果回顾性分析[J]. 检验医学与临床, 2020, 17(22):3275-3278.
[11] Huang WB, Zhang ME, Lu ZH, et al. Retrospective analysis of the identification results of 333 Mycobacterium species in Longyan City, Fujian Province[J]. Lab Med Clin, 2020, 17(22):3275-3278.
[12] 陈晓. 2009-2013年我院非结核分枝杆菌菌种分布及临床特点[C]. 杭州: 2014年浙江省检验医学学术年会, 2014.
[12] Chen X. Distribution and clinical characteristics of non-tuberculous mycobacterium species in our hospital from 2009 to 2013: Zhejiang Provincial Academic Conference on Laboratory Medicine[C]. Hangzhou:2014.
[13] Bjerrum S, Oliver-Commey J, Kenu E, et al. Tuberculosis and non-tuberculous mycobacteria among HIV-infected individuals in Ghana[J]. Trop Med Int Health, 2016, 21(9):1181-1190.
[14] Agizew T, Basotli J, Alexander H, et al. Higher-than-expected prevalence of non-tuberculous mycobacteria in HIV setting in Botswana: implications for diagnostic algorithms using Xpert MTB/RIF assay[J]. PLoS One, 2017, 12(12):e0189981.
[15] Chanda-Kapata P, Kapata N, Klinkenberg E, et al. Non-tuberculous mycobacteria (NTM) in Zambia: prevalence, clinical, radiological and microbiological characteristics[J]. BMC Infect Dis, 2015, 15:500.
[16] Karamat A, Ambreen A, Ishtiaq A, et al. Isolation of non-tuberculous mycobacteria among tuberculosis patients, a study from a tertiary care hospital in Lahore, Pakistan[J]. BMC Infect Dis, 2021, 21(1):381.
[17] Bouso JM, Planet PJ. Complete nontuberculous mycobacteria whole genomes using an optimized DNA extraction protocol for long-read sequencing[J]. BMC Genomics, 2019, 20(1):793.
[18] Deggim-Messmer V, Bloemberg GV, Ritter C, et al. Diagnostic molecular mycobacteriology in regions with low tuberculosis endemicity: combining real-time PCR assays for detection of multiple mycobacterial pathogens with line probe assays for identification of resistance mutations[J]. E Bio Medicine, 2016, 9:228-237.
[19] Genc GE, Demir M, Yaman G, et al. Evaluation of MALDI-TOF MS for identification of nontuberculous mycobacteria isolated from clinical specimens in mycobacteria growth indicator tube medium[J]. New Microbiol, 2018, 41(3):214-219.
[20] Akyar I, Çavuolu C, Aya M, et al. Evaluation of the performance of MALDI-TOF MS and DNA sequence analysis in the identification of mycobacteria species[J]. Turk J Med Sci, 2018, 48(6):1351-1357.
[21] Huang WC, Yu MC, Huang YW. Identification and drug susceptibility testing for nontuberculous mycobacteria[J]. J Formos Med Assoc, 2020, 119(Suppl 1):S32-S41.
[22] Mirzapour A, Alam AN, Bostanabadi SZ, et al. Identification of nontuberculous mycobacteria by high-performance liquid chromatography from patients in tehran[J]. Int J Mycobacteriol, 2016, 5(Suppl 1):S214.
[23] Baliga S, Murphy C, Sharon L, et al. Rapid method for detecting and differentiating Mycobacterium tuberculosis complex and non-tuberculous mycobacteria in sputum by fluorescence in situ hybridization with DNA probes[J]. Int J Infect Dis, 2018, 75:1-7.
[24] Matsumoto Y, Kinjo T, Motooka D, et al. Comprehensive subspecies identification of 175 nontuberculous mycobacteria species based on 7547 genomic profiles[J]. Emerg Microbes Infect, 2019, 8(1):1043-1053.
[25] Sharma S, Latawa R, Wanchu A, et al. Differential diagnosis of disseminated mycobacterium avium and Mycobacterium tuberculosis infection in HIV patients using duplex PCR[J]. Future Microbiol, 2021, 16(3):159-173.
Options
Outlines

/

〈 〉